Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

@article{Thomas2007PhaseIC,
  title={Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.},
  author={Eva S. Thomas and Josep Tabernero and Monica Nancy Fornier and Pierfranco Cont{\'e} and Pierre Fumoleau and A{\~n}a Lluch and Linda T. Vahdat and Craig A. Bunnell and Howard A. Burris and Patrice Viens and Jos{\'e} Baselga and Edgardo Rivera and Valentina Guarneri and Valerie Poulart and Judith V Klimovsky and David Edward Lebwohl and Miguel Mart{\'i}n},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 23},
  pages={3399-406}
}
PURPOSE Ixabepilone (BMS-247550) is an epothilone analog that optimizes the properties of naturally occurring epothilone B. Natural epothilones and their analogs promote tumor cell death by binding to tubulin and stabilizing microtubules, causing apoptosis. This international phase II trial assessed the activity of ixabepilone in patients with metastatic breast cancer (MBC) that was resistant to taxane therapy. PATIENTS AND METHODS MBC patients, who had experienced disease progression while… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 122 extracted citations

Similar Papers

Loading similar papers…